<DOC>
	<DOCNO>NCT00428337</DOCNO>
	<brief_summary>The purpose study determine safety immune response two experimental vaccine , design use combination , prevention HIV infection healthy adult .</brief_summary>
	<brief_title>Safety Immune Response DNA Vaccine Recombinant HIV-1-MVA Vaccine , Separately Combination , Healthy Adults</brief_title>
	<detailed_description>The worldwide HIV/AIDS epidemic may control development safe effective vaccine prevent HIV infection . DNA-based vaccine alone promote weak immune response use priming immunogen , follow recombinant viral vaccine attenuate vaccinia ( smallpox ) vaccine present immunogen booster , immunization combination regimen seem induce much strong response . EP-1233 DNA-HIV-recombinant vaccine design interact CD4 ( helper-inducer ) CD8 ( cytotoxic ) T lymphocytes ( T cell ) prime CD4 CD8 cell respond HIV component . MVA-mBN32 HIV-recombinant viral ( MVA ) vaccine way interact CD4 CD8 cell immunize ( boost ) similar HIV immunogen , may result strong immune response . The purpose study determine safety immune response two experimental vaccine prevention HIV infection , individually combination , healthy adult previously vaccinate smallpox . Participants randomly assign one three group . All participant receive injection Days 0 , 28 , 84 , 168 study . Participants assign Group 1 receive , Day 0 , one injection arm EP-1233 placebo study product ( EP-1233 DNA placebo ) Day 28 . Thereafter , Group 1 participant receive one injection MVA-mBN32 placebo Days 84 168 . Groups 2 3 begin enrollment safety immunogenicity data Group 1 evaluate . Participants assign Group 2 receive DNA vaccine EP-1233 ( placebo ) arm injection day . Participants Group 3 begin enrollment safety immunogenicity data Group 1 evaluate . Participants assign Group 3 receive consistent regimen MVA-mBN32 ( placebo ) injection day . Participants require keep symptom log 3 day injection attend clinical visit Day 0 , 14 , 28 , 42 , 84 , 98 , 168 , 182 , 273 , 364 study . At 10 visit , physical exam , cardiac assessment , HIV risk reduction prevention counsel occur . Blood collection occur Days 0 , 14 , 42 , 98 , 182 , 273 , 364 . Urine collection occur Days 14 , 42 , 98 , 182 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Good general health Previous receipt smallpox vaccination HIVinfected Hepatitis B surface antigen positive Participation prior HIV vaccination trial Immunosuppressive medication within 168 day prior study entry Receipt blood product within 120 day study entry Receipt live attenuate , medically indicated subunit , kill ( inactivate ) vaccine within 30 day study entry Certain abnormal lab value Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>HIV Seronegativity</keyword>
	<keyword>EP1233</keyword>
	<keyword>MVA-mBN32</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>